Depemokimab Reduces Exacerbations in Type 2 Asthma, CRSwNP Over 2 Years

Why It Matters

Twice‑yearly dosing could reshape severe type 2 asthma management by lowering treatment burden while delivering durable clinical benefits, positioning depemokimab as a strong competitor to existing biologics.

Key Takeaways

• Depemokimab cut asthma exacerbations 51% overall, 69% with CRSwNP
• Twice‑yearly 100 mg SC dosing maintained AER ~0.52 through 104 weeks
• SGRQ scores improved ~‑14 at 52 weeks, ‑16 at 104 weeks
• Serious adverse events occurred in 13% of patients; no treatment‑related deaths
• COVID‑19, nasopharyngitis, URIs were most common AEs, each ≤25%

Pulse Analysis

The phase III SWIFT‑1 and SWIFT‑2 trials introduced depemokimab as the first ultra‑long‑acting biologic for type 2 asthma, leveraging a 100 mg subcutaneous injection every six months. This dosing schedule contrasts sharply with the monthly or bi‑monthly regimens of established agents such as dupilumab and benralizumab, offering a potential reduction in clinic visits and adherence challenges. Over 762 participants, the integrated analysis demonstrated robust efficacy, particularly among the 80‑patient CRSwNP cohort, where exacerbation rates fell from 1.61 to 0.51 events per year.

Beyond raw exacerbation metrics, depemokimab delivered meaningful improvements in quality‑of‑life measures. The St. George’s Respiratory Questionnaire (SGRQ) dropped by 13.9 points at week 52 and deepened to 16.3 points by week 104, surpassing the minimal clinically important difference and indicating substantial symptom relief. Asthma Control Questionnaire‑5 scores also improved by 0.81 points, reinforcing the drug’s impact on daily disease control. These gains are especially relevant for patients with CRSwNP, a subgroup that traditionally experiences higher symptom burden and poorer response to standard therapies.

Safety data over two years showed an 86% overall adverse‑event rate, driven largely by common infections such as COVID‑19, nasopharyngitis, and upper‑respiratory‑tract infections, each affecting roughly a quarter of participants. Treatment‑related events were limited to 6%, and serious adverse events occurred in 13% without any treatment‑related fatalities. The manageable safety profile, combined with the convenience of semi‑annual dosing, positions depemokimab to capture market share from existing biologics, particularly among patients seeking fewer injections and sustained disease control.